Florentina Teofilovici

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski et al. · The Lancet · 2008 · 328 citations

Urology, Surgical Oncology, Versus Observation +10

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

Mark A. Socinski, Jonathan W. Goldman, Iman El‐Hariry et al. · Clinical Cancer Research · 2013 · 213 citations

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Suresh S. Ramalingam, Glenwood Goss, Rafael Rosell et al. · Annals of Oncology · 2015 · 106 citations · Full text

Oncology, Heat Shock, Medicine +7

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2)

Rathi N. Pillai, Dean A. Fennell, Vladimir Kovčin et al. · Journal of Clinical Oncology · 2019 · 70 citations

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Kwok‐Kin Wong, M. Koczywas, J. W. Goldman et al. · Journal of Clinical Oncology · 2011 · 62 citations

Cancer Epidemiology, Medicine, Hsp90 Inhibitor Ganetespib +14